Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (1199)	6/2/2002 2:37:49 PM
From: SemiBull	Read Replies (1) \| Respond to of 1298

Cell Genesys, Inc. Invites You to Join Its Company Presentation At the Needham & Company First Annual Biotechnology Conference FOSTER CITY, Calif., May 31 /PRNewswire-FirstCall/ -- In conjunction with Cell Genesys' (Nasdaq: CEGE - News) company presentation at the Needham & Company First Annual Biotechnology Conference, you are invited to listen to the presentation that will be broadcast live over the Internet on Tuesday, June 4, 2002, at 8:30 a.m. EDT with Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys. What: Cell Genesys, Inc. Company Presentation When: Tuesday, June 4, 2002, at 8:30 a.m. EDT Where: www.cellgenesys.com How: Live over the Internet -- Simply log on to the web at the address above Contact: Jennifer Cook Williams 650-425-4542 Cell Genesys is focused on the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and in vivo cancer gene therapies. Clinical trials of GVAX® vaccines are under way in lung cancer, prostate cancer, pancreatic cancer, leukemia and myeloma. Clinical trials of oncolytic virus therapies include CG7060 and CG7870 in prostate cancer. Preclinical stage programs include oncolytic virus therapies and gene therapies for multiple types of cancer. Cell Genesys' majority-owned subsidiary, Ceregene, is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold approximately nine million shares of common stock in its former subsidiary, Abgenix, an antibody products company. Cell Genesys is headquartered in Foster City, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company's website at www.cellgenesys.com. If you are unable to participate during the live webcast, the call will be archived on the web site, www.cellgenesys.com, for two weeks following the call. To access the replay, go to the Investor Relations section of the site. SOURCE: Cell Genesys, Inc.